Compare American Homes 4 Rent Class A (AMH) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
American Homes 4 Rent Class A vs Sana Biotechnology Inc — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while Sana Biotechnology Inc trades at $3.69 (market cap $1.07B). The key difference: American Homes 4 Rent Class A is far larger — about 11.2× Sana Biotechnology Inc's market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| AMH | SANA | |
|---|---|---|
Market Cap | $11.97B | $1.07B |
Sector | Real Estate | Health |
52-Week High | $36.74 | $5.92 |
52-Week Low | $27.38 | $2.68 |
Enterprise Value | $17.05B | $1.04B |
Dividend Yield | 3.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
SANA Biotechnology trades at $3.85, down 2.04% today, with a bullish technical outlook from moving averages but overbought RSI signals. The company shows significant losses with negative ROE of -147.41% and net income of -$244.17M for 2025, though cash burn is projected to improve in 2026. Recent news highlights clinical data presentations and a $69M stock sale via ATM facility in May 2026.
Despite heavy losses, analyst sentiment is strongly bullish with 82% buy ratings, reflecting optimism for SANA's engineered cell therapies. Key risks include sustained cash burn and clinical trial outcomes. The stock's appeal hinges on pipeline success, making it suitable for risk-tolerant investors betting on biotech innovation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
